Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13452)	5/10/2004 11:30:00 PM
From: Cal Gary	Respond to of 14101

For comparision: Novaritis' Lamisil sales in 2003 totalled USD $978 million. Within reach of the magic billion. Lamisil is ranked 4th on Novaritis' revenue generator scale. novartis.com Pharmaceuticals’ Top 10 Products 2003 Change Sales in Change in local USD millions in USD % currencies % Diovan/Co-Diovan 2 425 46 38 Gleevec/Glivec 1 128 84 68 Neoral/Sandimmun 1 020 -2 -10 Lamisil (group) 978 12 5 Zometa 892 83 74 Lotrel 777 20 20 Lescol 734 27 18 Sandostatin (group) 695 15 7 Voltaren (group) 599 1 -6 Cibacen/Lotensin/Cibadrex 433 -6 -9 Every 1% global market share = cool USD $10 million.

To: Cal Gary who wrote (13452)	5/11/2004 7:59:44 AM
From: winzer5	Read Replies (1) \| Respond to of 14101

And Now for Something Completely Different ........... Could this be the reason why she jettisoned the nail fungi fighter earlier this week? Reminds me of those Abbot & Costello type movies where the "bad guys" (or ones in pursuit) are catching up to the person sitting in the back of the jitney and the person in the back of the jitney is rolling pumpkins or empty barrels to thwart the pursuit. Hope for the beleagured shareholders yet? DMX must be worth fighting for then? Lucky thing REK set herself up for "the big exit" with the sweet deal some time ago. Winzer Start of NR============================= Dimethaid shareholder group seeks new board 2004-05-11 06:50 ET - News Release An anonymous director reports SHAREHOLDER GROUP REQUESTS CHANGES TO DIMETHAID DIRECTORS AND CEO After market close on Friday, May 7, 2004, a group of shareholders of Dimethaid Research requested that the company's board of directors replace all current directors with a slate proposed by the group. The group is also seeking the resignation of the chief executive officer. The group has indicated that it holds more than 5 per cent of the company's shares -- a sufficient quantity to requisition a special meeting of shareholders to seek approval of its proposed slate of directors. The group has indicated it would requisition a special meeting for that purpose, if it did not receive a satisfactory response from the board before 5 p.m. on Monday, May 10, 2004. The board has considered the request and is communicating with representatives of the group. The group has not communicated the total size of its holdings to the board. WARNING: The company relies upon litigation protection for "forward-looking" statements.